Earnings ·
Reports Q3 revenue of $0.2 million and net loss of $15.6 million
NAUTNautilus Biotechnology, Inc.
Nautilus Biotechnology reported third-quarter 2026 financial results with revenue of $0.2 million, primarily from grants and service fees under the Iterative Mapping Early Access Program. Operating expenses rose 10% to $16.9 million due to higher laboratory costs and salaries, resulting in a net loss of $15.6 million compared to $13.6 million in the prior-year period. The company ended the quarter with $114.3 million in cash, cash equivalents, and investments. Nautilus is a development-stage life sciences company pioneering single-molecule proteome analysis platforms.